Song Guangming, Liu Jue, Tang Xing, Zhong Jie, Zeng Yuhuan, Zhang Xiaodi, Zhou Jianbin, Zhou Jie, Cao Lu, Zhang Qunfeng, Li Yukun
Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Department of Assisted Reproductive Centre, The affiliated Zhuzhou hospital Xiangya medical college, Central South University, Zhuzhou, Hunan, China.
Front Pharmacol. 2024 Oct 11;15:1459057. doi: 10.3389/fphar.2024.1459057. eCollection 2024.
Malignant tumors are among the most important causes of death worldwide. The pathogenesis of a malignant tumor is complex and has not been fully elucidated. Studies have shown that such pathogenesis is related to abnormal cell cycle progression. The expression levels of cyclins, cyclin-dependent kinases (CDKs), and CDK inhibitors as well as functions of the cell cycle checkpoints determine whether the cell cycle progression is smooth. Cell-cycle-targeting drugs have the advantages of high specificity, low toxicity, low side effects, and low drug resistance. Identifying drugs that target the cell cycle and applying them in clinical treatments are expected to promote chemotherapeutic developments against malignant tumors. This article aims to review drugs targeted against the cell cycle and their action mechanisms.
恶性肿瘤是全球最重要的死亡原因之一。恶性肿瘤的发病机制复杂，尚未完全阐明。研究表明，这种发病机制与细胞周期进程异常有关。细胞周期蛋白、细胞周期蛋白依赖性激酶（CDK）和CDK抑制剂的表达水平以及细胞周期检查点的功能决定了细胞周期进程是否顺利。靶向细胞周期的药物具有特异性高、毒性低、副作用小和耐药性低等优点。识别靶向细胞周期的药物并将其应用于临床治疗有望推动恶性肿瘤化疗的发展。本文旨在综述靶向细胞周期的药物及其作用机制。
